Protocol and statistical analysis plan for a randomized controlled trial of the effect of intravenous iron on anemia in Malawian pregnant women in their third trimester (REVAMP - TT)
Journal Title
Gates Open Research
Publication Type
Protocol
Abstract
BACKGROUND: Anemia affects 40% of pregnant women globally, leading to maternal mortality, premature birth, low birth weight, and poor baby development. Iron deficiency causes over 40% of anemia cases in Africa. Oral iron supplementation is insufficient for Low-and-Middle-Income-Countries (LMICs) to meet current WHO targets. We hypothesized that a single intravenous dose of Ferric Carboxymaltose (FCM) may be more effective than oral iron treatment for anemia recovery, particularly in these settings where women present late for antenatal care. METHODS: This is a two-arm parallel open-label individual-randomized controlled trial in third trimester, in malaria Rapid Diagnostic Test-negative pregnant women with moderate or severe anemia - capillary hemoglobin <10 g/dL - who are randomized to receive either parenteral iron - with FCM - or standard-of-care oral iron for the remainder of pregnancy. This is the sister trial to the second-trimester REVAMP trial, funded by the Bill and Melinda Gates Foundation (trial registration ACTRN12618001268235, Gates Grant number INV-010612). In REVAMP-TT, recruitment and treatment are performed within primary health centers. The trial will recruit 590 women across Zomba district, Malawi. The primary outcome is the proportion of anemic women - venous hemoglobin <11 g/dL - at 36 weeks' gestation or delivery (whichever occurs first). Other pre-specified key secondary clinical and safety outcomes include maternal iron-status and hypophosphatemia, neonate birth weight, infant growth and infant iron and hematological parameters. DISCUSSION: This study will determine whether FCM, delivered within primary health centers, is effective, safe and feasible for treating moderate to severe anemia in third-trimester pregnant Malawian women. This intervention could have long-term benefits for maternal and child health, resulting in improved survival and child development.
Keywords
Infant, Newborn; Child; Female; Humans; Pregnancy; Iron/therapeutic use; Pregnancy Trimester, Third; Pregnant Women; *Anemia, Iron-Deficiency/drug therapy; *Anemia/drug therapy; Hemoglobins/analysis; Malawi/epidemiology; Randomized Controlled Trials as Topic; *Ferric Compounds; Maltose/*analogs & derivatives; Anemia; Birth weight; Iron; Iron-deficiency; Rct
Department(s)
Clinical Haematology
PubMed ID
38343768
Open Access at Publisher's Site
https://doi.org/10.12688/gatesopenres.14710.2
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-08-20 06:08:18
Last Modified: 2024-08-20 06:56:56

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙